If there is anything that the COVID-19 pandemic has taught us, it is that roll out of any new medicine to combat the virus will be slow, disorganised and mostly horded by richer nations to the detriment of everyone. Just look at the roll out of vaccines, the highest income countries were vaccinating more than 20 times faster than the lowest. As a new drug, Molnupiravir will likely be extremely expensive to produce and companies like Ridgeback Biotherapeutics & Merck & Co. are unlikely to bypass their monopoly and pass up the chance to profit monetarily, as a result new antiviral drugs are likely to do as well as vaccines have as they will be so slow to roll out globally. If we look at the other antivirals that saw limited use in the COVID19 pandemic, such as Remdesivir, the situation looks less than promising, side effects were awful with around 25% of patients that received the drug suffering very severe side effects, including multiple-organ dysfunction syndrome, septic shock, and acute kidney injury. We really need side effect data before we can say anything, but some other nucleoside analogue drugs, similar to Molnupiravir, have even caused birth defects in animal studies, it would be a miracle if this drug was not without serious side effects.